Effects of URB597, an inhibitor of fatty acid amide hydrolase (FAAH), on analgesic activity of paracetamol

Neuroendocrinology Letters

Volumn 31, Issue 4, 2010, Pages 507-511

  Soukupová, Marie ^a,b   Palazzo, Enza ^b   De Chiaro, Maria ^b   Gatta, Luisa ^b   Migliozzi, Anna Lucia ^b   Guida, Francesca ^a,b   Luongo, Livio ^b   Giordano, Catia ^b   Siniscalco, Dario ^b   De Novellis, Vito ^b   Marabese, Ida ^b   Kršiak, Miloslav ^a   Maione, Sabatino ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Seconda Universita degli Studi di Napoli Facolta di Medicina e Chirurgia   (Italy)

Author keywords

AM404; FAAH; Mechanism of action; Paracetamol; URB597

Indexed keywords

CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; FATTY ACID AMIDASE; PARACETAMOL;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; MALE; MOUSE; NONHUMAN;

EID: 77957871761     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D (1997). Functional role of high affinity anandamide transport, as revealed by selective inhibition. Science 277(5329): 1094-1097. (Pubitemid 27371630)
2. Bertolini A, Ferrari A, Ottani A, Guerzoni S, Tacchi R, Leone S (2006). Paracetamol: new vistas of an old drug. CNS Drug Rev 12(3-4): 250-275. (Pubitemid 46047791)
3. Björkman R, Hallman KM, Hedner J, Hedner T, Henning M (1994). Acetaminophen blocks spinal hyperalgesia induced by NMDA and substance P. Pain 57(3): 259-264. (Pubitemid 24197326)
4. Borsani E, Labanca M, Bianchi R, Rodella LF (2007). AM404 decreases Fos-immunoreactivity in the spinal cord in a model of inflammatory pain. Brain Res 1152: 87-94. (Pubitemid 46802512)
5. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384: 83-87.
6. De Novellis V, Palazzo E, Rossi F, De Petrocellis L, Petrosino S, Guida F, et al (2008) The analgesic effect of N-arachidonoyl-serotonin, a FAAH inhibitor and TRPV1 receptor antagonist, associated with changes in rostral ventromedial medulla and locus coeruleus cell activity in rats. Neuropharmacology 55: 1105-1113.
7. De Petrocellis L, Bisogno T, Davis JB, Pertwee RG, Di Marzo V (2000). Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett 483(1): 52-56.
8. Fegley D, Kathuria S, Mercier R, Li C, Goutopoulos A, Makriyannis A, et al (2004). Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc Natl Acad Sci U S A 101(23): 8756-8761.
9. Glaser ST, Abumrad NA, Fatade F, Kaczocha M, Studholme KM, Deutsch DG (2003). Evidence against the presence of an anandamide transporter. Proc Natl Acad Sci U S A 100(7): 4269-4274.
10. Haller VL, Cichewicz DL, Welch SP (2006). Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice. Eur J Pharmacol 546: 60-68.
11. Hasanein P, Shahidi S, Komaki A, Mirazi N (2008). Effects of URB597 as an inhibitor of fatty acid amide hydrolase on modulation of nociception in a rat model of cholestasis. Eur J Pharmacol 591: 132-135.
12. Hasanein P (2009). The endocannabinoid transport inhibitor AM404 modulates nociception in cholestasis. Neurosci Lett 462(3): 230-234.
13. Högestätt ED, Jönsson BA, Ermund A, Andersson DA, Björk H, Alexander JP, et al (2005). Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. J Biol Chem 280(36): 31405-31412.
14. Jain NK, Kulkarni SK, Singh A (2002). Modulation of NSAID-induced antinociceptive and anti-inflammatory effects by alpha2-adrenoceptor agonists with gastroprotective effects. Life Sci 70(24): 2857-2869.
15. Jayamanne A, Greenwood R, Mitchell VA, Asian S, Piomelli D, Vaughan CW (2006). Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol 147: 281-288. (Pubitemid 43214685)
16. Lichtman AH, Leung D, Shelton CC, Saghatelian A, Hardouin C, Boger DL, et al (2004). Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 311: 441-448. (Pubitemid 39391527)
17. Maione S, Bisogno T, De Novellis V, Palazzo E, Cristino L, Valenti M, et al (2006). Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exp Ther 316: 969-982.
18. Maione S, De Petrocellis L, de Novellis V, Moriello AS, Petrosino S, Palazzo E, et al (2007). Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol 150(6): 766-781.
19. Mallet C, Daulhac L, Bonnefont J, Ledent C, Etienne M, Chapuy E, et al (2008). Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia. Pain 139(1): 190-200.
20. Mitchell VA, Greenwood R, Jayamanne A, Vaughan CW (2007). Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models. Clin Exp Pharmacol Physiol 34(11): 1186-1190. (Pubitemid 47416352)
21. Ruggieri V, Vitale G, Pini LA, Sandrini M (2008). Differential involvement of opioidergic and serotonergic systems in the anti-nociceptive activity of N-arachidonoyi-phenolamine (AM404) in the rat: comparison with paracetamol. Naunyn Schmiedebergs Arch Pharmacol 377(3): 219-229.
22. Sinning C, Watzer B, Coste O, Nusing RM, Ott I, Ligresti A, ef al (2008). New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide. J Med Chem 51: 7800-7805.
23. Tallarida RJ (2000). Drug synergism and dose-effect analysis. Boca Raton (Florida): Chapman & Hall/CRC.
24. Tallarida RJ (2001). Drug synergism: Its detection and applications. J Pharmacol Exp Ther 298: 865-872.
25. Tallarida RJ (2002). The interaction index: a measure of drug synergism. Pain 98: 163-168.
26. Tallarida RJ (2006). An overview of drug combination analysis with isobolograms. J Pharmacol Exp Ther 319: 1-7.
27. Tallarida RJ (2007). Interactions between drugs and occupied receptors. Pharmacol Therapeut 113: 197-209.
28. Zimmermann M (1983). Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16: 109-110.
29. Zygmunt PM, Chuang H, Movahed P, Julius D, Högestätt ED (2000). The anandamide transport inhibitor AM404 activates vanilloid receptors. Eur J Pharmacol 396(1): 39-42. (Pubitemid 30261557)